Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a novel coronavirus that causes a highly contagious respiratory disease, SARS, with significant mortality. Although factors contributing to the highly pathogenic nature of SARS-CoV remain poorly understood, it has been reported that SARS-CoV infection does not induce type I interferons (IFNs) in cell culture. However, it is uncertain whether SARS-CoV evades host detection or has evolved mechanisms to counteract innate host defenses. We show here that infection of SARS-CoV triggers a weak IFN response in cultured human lung/bronchial epithelial cells without inducing the phosphorylation of IFN-regulatory factor 3 (IRF-3), a latent cellular transcription factor that is pivotal for type I IFN synthesis. Furthermore, SARS-CoV infection blocked the induction of IFN antiviral activity and the up-regulation of protein expression of a subset of IFN-stimulated genes triggered by double-stranded RNA or an unrelated paramyxovirus. In searching for a SARS-CoV protein capable of counteracting innate immunity, we identified the papain-like protease (PLpro) domain as a potent IFN antagonist. The inhibition of the IFN response does not require the protease activity of PLpro. Rather, PLpro interacts with IRF-3 and inhibits the phosphorylation and nuclear translocation of IRF-3, thereby disrupting the activation of type I IFN responses through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-associated gene 5 pathways. Our data suggest that regulation of IRF-3-dependent innate antiviral defenses by PLpro may contribute to the establishment of SARS-CoV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(ii) the papain‐like protease domain of CoV‐NL63 binds BECN1 and STING1, thus hindering BECN1‐mediated autophagosome formation and inhibiting IFN production (Devaraj et al, 2007; Chen et al, 2014)”
From Autophagy in major human diseases (2021) · cites this paper as Devaraj et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 3,929
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Self-citationIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., & Akira, S. (2005) · Nature Immunology · doi:10.1038/ni1243 · Cited by 2,562
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Cited by
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
“SARS-CoV PLpro disrupts NF-κB signalling 73 and blocks the phosphorylation of IRF3 indirectly 73,74 .”
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
“Other proteins, including SARS-CoV-1 PLP, N, ORF3b and ORF6, block IRF3 phosphorylation and nuclear translocation (Devaraj et al., 2007; .”
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
Harrison, A. G., Lin, T., & Wang, P. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.10.004 · Cited by 1,186
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., Schulz, L., Widera, M., Mehdipour, A. R., Tascher, G., et al. (2020) · Nature · doi:10.1038/s41586-020-2601-5 · Cited by 1,177
Human Coronavirus: Host-Pathogen Interaction
Fung, T. S., & Liu, D. X. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115759 · Cited by 960
“Nonetheless, HCoV PLPro could also antagonize innate immunity by mechanisms independent of its deubiquitinating/deISGylating activity (29).”
BackgroundWeiss, S. R., & Leibowitz, J. L. (2011) · Advances in Virus Research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 896
“Indeed, several studies have demonstrated that PLP of SARS-CoV inhibits both the IRF3 and NF-kB pathways (Devaraj et al., 2007; Frieman et al., 2009).”
BackgroundType I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Báez-Santos, Y. M., St. John, S. E., & Mesecar, A. D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2014.12.015 · Cited by 854
Viral evasion and subversion of pattern-recognition receptor signalling
Bowie, A. G., & Unterholzner, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2436 · Cited by 746
Toll-Like Receptors in Antiviral Innate Immunity
Lester, S. N., & Li, K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.024 · Cited by 735
“This interaction prevents phosphorylation and nuclear translocation of IRF3 following engagement of TLR3 andRLRpathways [204].”
BackgroundSelf-citationNsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
“Furthermore, the PL2pro was found not to block the NF-κB signaling pathway and the protease activity was described as dispensable for antagonizing the IFN response (Devaraj et al., 2007).”
BackgroundFrom SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
“The deubiquitinase activity of the enzyme interferes, in an as-yet unknown way, with the phosphorylation and nuclear import of interferon-regulatory factor 3 (IRF3) and thereby prevents the production of type-I interferons by the infected host cell [71] [72] [73] .”
BackgroundHuman Coronaviruses: A Review of Virus–Host Interactions
Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 591
The molecular virology of coronaviruses
Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013930 · Cited by 525
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Yuen, C.-K., Lam, J.-Y., Wong, W.-M., Mak, L.-F., Wang, X., Chu, H., Cai, J.-P., Jin, D.-Y., To, K. K.-W., Chan, J. F.-W., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780953 · Cited by 524
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Self-citationOverview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 475
“, PLpro and ORF3b, inhibit IRF3 phosphorylation and hence its translocation to the nucleus (4, 107, 108).”
BackgroundRut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipas, S. J., El Oualid, F., Huang, T. T., Bekes, M., Drag, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.abd4596 · Cited by 459
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
“Inhibits IRF3 phosphorylation IRF3 activation Protein overexpression HEK293, HeLa, and MA104 cells [30, 39]”
MethodAntiviral activities of type I interferons to SARS-CoV-2 infection
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104811 · Cited by 426
“, 2008), nonstructural protein nsp3 (Devaraj et al., 2007; Frieman et al., 2009; Sun et al., 2012), and the accessory protein ORF3b, ORF6, ORF8a and 8 ab (Freundt et al.”
Narayanan, K., Huang, C., Lokugamage, K., Kamitani, W., Ikegami, T., Tseng, C.-T. K., & Makino, S. (2008) · Journal of Virology · doi:10.1128/jvi.02472-07 · Cited by 427
“It has been shown that SARS-CoV replication in the human lung epithelial cell line Calu3 and in the rhesus monkey-derived fibroblast cell line MA104 triggers a weak induction of IFN- mRNA (8).”
BackgroundSelf-citationSARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway
Khan, S., Shafiei, M. S., Longoria, C., Schoggins, J. W., Savani, R. C., & Zaki, H. (2021) · eLife · doi:10.7554/elife.68563 · Cited by 398
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
Totura, A. L., & Baric, R. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.04.004 · Cited by 415
“Part of the third nonstructural protein, SARS-CoV PLP is a papain like protease that antagonizes IFN by blocking phosphorylation IRF3 [76] .”
BackgroundDrexler, J. F., Gloza-Rausch, F., Glende, J., Corman, V. M., Muth, D., Goettsche, M., Seebens, A., Niedrig, M., Pfefferle, S., Yordanov, S., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00650-10 · Cited by 392
Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.02220-08 · Cited by 368
“IKKi, IKK , and TBK1 kinases were purchased from Invitrogen, while I B and NF- B (p50) were purchased from Biomol International.”
BackgroundResultInfluentialKirtipal, N., Bharadwaj, S., & Kang, S. G. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104502 · Cited by 306
“Besides, PL was reported to cause deubiquitination (or inhibit ubiquitination) of Tank-binding kinase 1 (TBK1), RIGI, and IRF3 (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009; Sun et al., 2012).”
InfluentialThe deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy
Cornelissen, T., Haddad, D., Wauters, F., Van Humbeeck, C., Mandemakers, W., Koentjoro, B., Sue, C., Gevaert, K., De Strooper, B., Verstreken, P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu244 · Cited by 327
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases
Clementz, M. A., Chen, Z., Banach, B. S., Wang, Y., Sun, L., Ratia, K., Baez-Santos, Y. M., Wang, J., Takayama, J., Ghosh, A. K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02406-09 · Cited by 308
“HEK293 cells were transfected with plasmid DNA encoding the transmembrane form of PLpro-TM (amino acids 1541 to 2425 of SARS-CoV ORF 1a), previously shown to be a potent IFN antagonist (13), and pRL-TK along with the IFN- , ISRE, or NF- B reporter, and an nsp2/3-GFP substrate.”
BackgroundMethodResultInfluentialSelf-citationCritical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
“Hence, SARSCoV-2 PLpro inhibits IRF3 activation and antagonizes the type I IFN response (140, 141).”
BackgroundInfluentialBacterial co‐infections with SARS‐CoV‐2
Mirzaei, R., Goodarzi, P., Asadi, M., Soltani, A., Aljanabi, H. A. A., Jeda, A. S., Dashtbin, S., Jalalifar, S., Mohammadzadeh, R., Teimoori, A., et al. (2020) · IUBMB Life · doi:10.1002/iub.2356 · Cited by 291
Freitas, B. T., Durie, I. A., Murray, J., Longo, J. E., Miller, H. C., Crich, D., Hogan, R. J., Tripp, R. A., & Pegan, S. D. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00168 · Cited by 290
Type I and III interferon responses in SARS-CoV-2 infection
Kim, Y.-M., & Shin, E.-C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00592-0 · Cited by 296
Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response
Kindler, E., Thiel, V., & Weber, F. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.006 · Cited by 290
“…TRAF6 Shi et al. (2014) MERS-CoV ORF4a protein Interacts with dsRNA and the RLR cofactor PACT Niemeyer et al. (2013) MERS-CoV ORF4a protein Interacts with the RLR cofactor PACT Siu et al. (2014) TBK1, and IRF3 (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009; Sun et al., 2012).”
BackgroundInfluentialMoustaqil, M., Ollivier, E., Chiu, H.-P., Van Tol, S., Rudolffi-Soto, P., Stevens, C., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 283
“deubiquitinase and deISGylation activity that contribute to inhibition of IRF3 activity [16,21,22,44,61].”
BackgroundSARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
Neufeldt, C. J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.-Y., Plociennikowska, A., Heigwer, F., Prasad, V., Joecks, S., Burkart, S. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02983-5 · Cited by 272
Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., Zhao, Z., & Tan, W. (2013) · Protein & Cell · doi:10.1007/s13238-013-3096-8 · Cited by 277
“…proteins (van Boheemen et al., 2012); it thus remains a possibility that one or more of these products also inhibit the interferon response, much like SARS-CoV (Devaraj et al., 2007; Wathelet et al., 2007; Frieman et al., 2009; Kamitani, et al., 2009; Huang et al., 2011; Sun et al., 2012).”
BackgroundInfluentialWu, J., Shi, Y., Pan, X., Wu, S., Hou, R., Zhang, Y., Zhong, T., Tang, H., Du, W., Wang, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108761 · Cited by 265
Siu, K.-L., Kok, K.-H., Ng, M.-H. J., Poon, V. K. M., Yuen, K.-Y., Zheng, B.-J., & Jin, D.-Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008227 · Cited by 272
Sun, L., Xing, Y., Chen, X., Zheng, Y., Yang, Y., Nichols, D. B., Clementz, M. A., Banach, B. S., Li, K., Baker, S. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030802 · Cited by 268
“However, we had previously shown that catalytically defective PLP mutants were still capable of inhibiting IRF-3 activation [17].”
InfluentialSelf-citationSpread, Circulation, and Evolution of the Middle East Respiratory Syndrome Coronavirus
Cotten, M., Watson, S. J., Zumla, A. I., Makhdoom, H. Q., Palser, A. L., Ong, S. H., Al Rabeeah, A. A., Alhakeem, R. F., Assiri, A., Al-Tawfiq, J. A., et al. (2014) · mBio · doi:10.1128/mbio.01062-13 · Cited by 266
“The viral papain-like protease (PLP) is required for cleavage of the open reading frame 1A (ORF1a) polyprotein and may antagonize host immune signaling (26, 27).”
BackgroundChen, X., Yang, X., Zheng, Y., Yang, Y., Xing, Y., & Chen, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0026-3 · Cited by 272
“Multiple SARS coronaviral proteins, such as ORF3b, ORF6, N, M, and nsp1, have been suggested to inhibit IFN production (Kamitani et al., 2006; Devaraj et al., 2007; Frieman et al., 2007; Kopecky-Bromberg et al., 2007; Wathelet et al., 2007; Zust et al., 2007; Narayanan et al., 2008; Siu et al.,…”
Self-citationTanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases
Park, J.-Y., Kim, J. H., Kim, Y. M., Jeong, H. J., Kim, D. W., Park, K. H., Kwon, H.-J., Park, S.-J., Lee, W. S., & Ryu, Y. B. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.07.038 · Cited by 258
Báez-Santos, Y. M., Barraza, S. J., Wilson, M. W., Agius, M. P., Mielech, A. M., Davis, N. M., Baker, S. C., Larsen, S. D., & Mesecar, A. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401712t · Cited by 255
Self-citationPost-Translational Modifications of Coronavirus Proteins: Roles and Function
Fung, T. S., & Liu, D. X. (2018) · Future Virology · doi:10.2217/fvl-2018-0008 · Cited by 238
“Initial studies identified SARS-CoV PLPro as a potent IFN antagonist by interacting with IRF3 and inhibiting its phosphorylation and nuclear translocation, thereby blocking type I IFN production [189] .”
BackgroundLu, X., Pan, J., Tao, J., & Guo, D. (2011) · Virus Genes · doi:10.1007/s11262-010-0544-x · Cited by 235
Fehr, A. R., Channappanavar, R., Jankevicius, G., Fett, C., Zhao, J., Athmer, J., Meyerholz, D. K., Ahel, I., & Perlman, S. (2016) · mBio · doi:10.1128/mbio.01721-16 · Cited by 233
“It has long been known that SARS-CoV is able to repress the cellular IFN response, and a number of SARS-CoV proteins have been shown to block the IFN response in isolation or in vitro (43) (44) (45) (46) (47) .”
Innate immune sensing of coronavirus and viral evasion strategies
Kasuga, Y., Zhu, B., Jang, K.-J., & Yoo, J.-S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00602-1 · Cited by 228
MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
Mielech, A. M., Kilianski, A., Baez-Santos, Y. M., Mesecar, A. D., & Baker, S. C. (2014) · Virology · doi:10.1016/j.virol.2013.11.040 · Cited by 231
“MERS-CoV PLpro is an interferon and NF-κB antagonist Coronavirus PLPs have been shown to block interferon β (IFNβ) induction in transfected cells (Clementz et al., 2010; Frieman et al., 2009; Devaraj et al., 2007).”
BackgroundInfluentialSelf-citationRatia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C., & Mesecar, A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004113 · Cited by 224
“Though the exact cellular targets for these accessory activities are unknown, PLpro has been directly linked to suppressing interferon-b (IFNb) production by the innate immune response during virus infection [26].”
BackgroundSelf-citationDing, Z., Fang, L., Jing, H., Zeng, S., Wang, D., Liu, L., Zhang, H., Luo, R., Chen, H., & Xiao, S. (2014) · Journal of Virology · doi:10.1128/jvi.00700-14 · Cited by 218
Wang, N., Liang, Y., Devaraj, S., Wang, J., Lemon, S. M., & Li, K. (2009) · Journal of Virology · doi:10.1128/jvi.01125-09 · Cited by 209
Self-citationKim, D. W., Seo, K. H., Curtis-Long, M. J., Oh, K. Y., Oh, J.-W., Cho, J. K., Lee, K. H., & Park, K. H. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.753591 · Cited by 208
“Due to its potency, subsequent bioactivity-guided fractionation of the ethanol extract led to six aromatic compounds (1–6), which were identified as bavachinin (1), neobavaisoflavone (2), isobavachalcone (3), 40-O-methylbavachalcone (4), psoralidin (5) and corylifol A (6).”
BackgroundMethodInfluentialType I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
Mazewski, C., Perez, R. E., Fish, E. N., & Platanias, L. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606456 · Cited by 198
Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunity
Barral, P. M., Sarkar, D., Su, Z.-Z., Barber, G. N., DeSalle, R., Racaniello, V. R., & Fisher, P. B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.012 · Cited by 200
“The papain-like protease of SARS virus binds IRF3 and prevents dimerization, thereby inhibiting nuclear translocation (Devaraj et al., 2007).”
Wang, D., Fang, L., Li, P., Sun, L., Fan, J., Zhang, Q., Luo, R., Liu, X., Li, K., Chen, H., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02589-10 · Cited by 186
“Like the coronaviral papain-like proteases, including SARS-CoV PLpro, MHV A59 PLP2, and HCoV NL63 PLP2, and the cysteine protease of an arterivirus, i.e., the nonstructural protein 2 (NSP2) of porcine reproductive and respiratory syndrome virus, Lbpro possesses deubiquitination activity and is able to antagonize innat…”
BackgroundSelf-citationMielech, A. M., Chen, Y., Mesecar, A. D., & Baker, S. C. (2014) · Virus Research · doi:10.1016/j.virusres.2014.01.025 · Cited by 179
Self-citationXing, J., Wang, S., Lin, R., Mossman, K. L., & Zheng, C. (2012) · Journal of Virology · doi:10.1128/jvi.06713-11 · Cited by 179
“To determine which region of US11 was responsible for the inhibition of virus-mediated activation of the IFN- promoter, a series of US11 WT and recombinant plasmids constructed previously (89), including US11-EYFP, US11(1-83)-EYFP, US11(84-152)EYFP, US11(84-125)-EYFP, and US11(126-152)-EYFP, were employed in this stud…”
BackgroundMethodSelf-citationWang, D., Fang, L., Shi, Y., Zhang, H., Gao, L., Peng, G., Chen, H., Li, K., & Xiao, S. (2016) · Journal of Virology · doi:10.1128/jvi.02514-15 · Cited by 176
Self-citationLi, S.-W., Wang, C.-Y., Jou, Y.-J., Huang, S.-H., Hsiao, L.-H., Wan, L., Lin, Y.-J., Kung, S.-H., & Lin, C.-W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050678 · Cited by 176
“The finding was also similar to previous reports in that the inhibitory effect of SARS-CoV PLPro on the inactivation of the transcription factors IRF3 and NF-κB has been demonstrated to correlate with PLPro-reduced ubiquitination of RIG-I, STING TRAF3, TBK1 and IRF3 in the TLR3 and RIG-I pathways [16,17].”
MethodResultYang, D., Chu, H., Hou, Y., Chai, Y., Shuai, H., Lee, A. C.-Y., Zhang, X., Wang, Y., Hu, B., Huang, X., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa356 · Cited by 179
Coronavirus virulence genes with main focus on SARS-CoV envelope gene
DeDiego, M. L., Nieto-Torres, J. L., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Usera, F., & Enjuanes, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.07.024 · Cited by 177
“SARS-CoV proteins N, 3b and 6 prevent IFN production by locking IRF-3 phosphorylation (Devaraj et al., 2007; Freundt et al., 009; Frieman et al., 2009; Kopecky-Bromberg et al., 2007).”
InfluentialThe SARS-Unique Domain (SUD) of SARS Coronavirus Contains Two Macrodomains That Bind G-Quadruplexes
Tan, J., Vonrhein, C., Smart, O. S., Bricogne, G., Bollati, M., Kusov, Y., Hansen, G., Mesters, J. R., Schmidt, C. L., & Hilgenfeld, R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000428 · Cited by 169
Xing, Y., Chen, J., Tu, J., Zhang, B., Chen, X., Shi, H., Baker, S. C., Feng, L., & Chen, Z. (2013) · Journal of General Virology · doi:10.1099/vir.0.051169-0 · Cited by 165
“While many reports have demonstrated that cellular and viral DUBs play important roles in negative regulation of host innate immunity, as discussed as below, future work will be needed to determine the exact functions of PLP2 protease/DUB activity in coronavirus interaction with host innate immune response.”
BackgroundMethodInfluentialSelf-citationCoronavirus interactions with the cellular autophagy machinery
Miller, K., McGrath, M. E., Hu, Z., Ariannejad, S., Weston, S., Frieman, M., & Jackson, W. T. (2020) · Autophagy · doi:10.1080/15548627.2020.1817280 · Cited by 163
Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice
DeDiego, M. L., Pewe, L., Alvarez, E., Rejas, M. T., Perlman, S., & Enjuanes, L. (2008) · Virology · doi:10.1016/j.virol.2008.03.005 · Cited by 161
“Some of these genes may have redundant functions, as it has been shown that genes 3b, 6, N, nsp1, and nsp3 may all act as interferon antagonists (Devaraj et al., 2007; Frieman et al., 2007; KopeckyBromberg et al., 2007; Wathelet et al., 2007).”
Foot-and-Mouth Disease Virus 3C Protease Cleaves NEMO To Impair Innate Immune Signaling
Wang, D., Fang, L., Li, K., Zhong, H., Fan, J., Ouyang, C., Zhang, H., Duan, E., Luo, R., Zhang, Z., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00722-12 · Cited by 162
“respiratory syndrome coronavirus (SARS-CoV) PLpro (14), hu-”
Self-citationYang, X., Chen, X., Bian, G., Tu, J., Xing, Y., Wang, Y., & Chen, Z. (2014) · Journal of General Virology · doi:10.1099/vir.0.059014-0 · Cited by 154
“6a, the IFN-b promoter was activated 100-fold when the cells were transfected with RIG-IN, whereas the IFN-b promoter activated by RIG-IN was completely inhibited in the presence of MERS-CoV PLpro-TM, which was similar to the previously reported IFN antagonist activity of SARSCoV PLpro and NL63-CoV PLP2 (Clementz et a…”
BackgroundMethodResultInfluentialSelf-citationEriksson, K. K., Cervantes-Barragán, L., Ludewig, B., & Thiel, V. (2008) · Journal of Virology · doi:10.1128/jvi.02082-08 · Cited by 155
“For example, the coronaviral X domain is expressed on nsp3 together with papain-like proteinase domains that have been shown to possess deubiquitinating activity and to function as an IFN antagonist (2, 7, 18).”
BackgroundInfluentialPorcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines
Li, Z., Ma, Z., Li, Y., Gao, S., & Xiao, S. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104553 · Cited by 158
“The PLpro of SARS-CoV interacts with IRF3 and inhibits the phosphorylation and nuclear translocation of IRF-3, thereby disrupting the activation of the type I IFN pathway through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-related gene 5 pathways in vitro [38].”
BackgroundBailey-Elkin, B. A., Knaap, R. C. M., Johnson, G. G., Dalebout, T. J., Ninaber, D. K., van Kasteren, P. B., Bredenbeek, P. J., Snijder, E. J., Kikkert, M., & Mark, B. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.609644 · Cited by 152
“Coronavirus papain-like proteases have been suggested to act as IFN- and NF- B antagonists as well (15, 23, 66, 67).”
BackgroundRut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipas, S. J., Oualid, F. E., Huang, T. T., Bekes, M., Drąg, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.29.068890 · Cited by 152
Ghosh, A. K., Takayama, J., Rao, K. V., Ratia, K. M., Chaudhuri, R., Mulhearn, D. C., Lee, H., Nichols, D. B., Baliji, S., Baker, S. C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004489 · Cited by 151
Self-citationWang, S., Wang, K., Lin, R., & Zheng, C. (2013) · Journal of Virology · doi:10.1128/jvi.02355-13 · Cited by 154
“Thus, viruses are more likely to evolve strategies, such as varicella-zoster virus (VZV) ORF61 (44), VZV ORF47 (66), the severe acute respiratory coronavirus (SARSCoV) papain-like protease domain (67), human bocavirus NP1 (68), etc.”
BackgroundSelf-citationXing, J., Ni, L., Wang, S., Wang, K., Lin, R., & Zheng, C. (2013) · Journal of Virology · doi:10.1128/jvi.01440-13 · Cited by 156
Self-citationKim, O., Sun, Y., Lai, F. W., Song, C., & Yoo, D. (2010) · Virology · doi:10.1016/j.virol.2010.03.039 · Cited by 175
Yoo, D., Song, C., Sun, Y., Du, Y., Kim, O., & Liu, H. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.019 · Cited by 162
Global virus outbreaks: Interferons as 1st responders
Wang, B. X., & Fish, E. N. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101300 · Cited by 148
Wong, N. A., & Saier, M. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031308 · Cited by 161
Zhu, H., Zheng, C., Xing, J., Wang, S., Li, S., Lin, R., & Mossman, K. L. (2011) · Journal of Virology · doi:10.1128/jvi.05098-11 · Cited by 140
Self-citationGhosh, A. K., Takayama, J., Aubin, Y., Ratia, K., Chaudhuri, R., Baez, Y., Sleeman, K., Coughlin, M., Nichols, D. B., Mulhearn, D. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900611t · Cited by 129
Self-citationZheng, D., Chen, G., Guo, B., Cheng, G., & Tang, H. (2008) · Cell Research · doi:10.1038/cr.2008.294 · Cited by 135
“During our study, another group reported a similar phenomenon that SCoV PLpro could block IRF3-mediated type I IFN induction [28] .”
InfluentialYang, Y., Ye, F., Zhu, N., Wang, W., Deng, Y., Zhao, Z., & Tan, W. (2015) · Scientific Reports · doi:10.1038/srep17554 · Cited by 132
Taylor, J. K., Coleman, C. M., Postel, S., Sisk, J. M., Bernbaum, J. G., Venkataraman, T., Sundberg, E. J., & Frieman, M. B. (2015) · Journal of Virology · doi:10.1128/jvi.02274-15 · Cited by 137
Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J. J., Zhao, J., Zhang, S., Wang, T.-Y., Carriere, J., Savas, A. C., et al. (2021) · mBio · doi:10.1128/mbio.02335-21 · Cited by 129
Węglarz‐Tomczak, E., Tomczak, J. M., Talma, M., Burda‐Grabowska, M., Giurg, M., & Brul, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83229-6 · Cited by 133
Chen, X., Wang, K., Xing, Y., Tu, J., Yang, X., Zhao, Q., Li, K., & Chen, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0104-6 · Cited by 130
“3), its expression was strongly induced in cells expressing SARS-CoV PLpro-TM (lane 3, Fig.”
BackgroundMethodResultInfluentialSelf-citationBáez-Santos, Y. M., Mielech, A. M., Deng, X., Baker, S., & Mesecar, A. D. (2014) · Journal of Virology · doi:10.1128/jvi.01294-14 · Cited by 128
Self-citationvan Kasteren, P. B., Beugeling, C., Ninaber, D. K., Frias‐Staheli, N., van Boheemen, S., García‐Sastre, A., Snijder, E. J., & Kikkert, M. (2011) · Journal of Virology · doi:10.1128/jvi.06277-11 · Cited by 140
“For the mammalian expression constructs of the CCHFV DUB domain, a fragment encoding aa 1 to 169 of the L protein was transferred from pCAGGSHA-L(1-169) wild type and C40A/H151A (15) to the pcDNA3.”
BackgroundResultInfluentialThe yin and yang of viruses and interferons
Wang, B. X., & Fish, E. N. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.004 · Cited by 116
“Specifically, Nsp3 inhibits IRF3 in human bronchial epithelial cells via its papain-like protease (PLP) domain, which [4, 76] , tripartite motif-containing protein 5a (TRIM5a) and TRIM22, which are antiviral factors that limit HIV-1 infection [77] , and transcription factor jun-D (JUND) and claudin 4 (CLDN4) [78] .”
Pišlar, A. H., Mitrović, A., Sabotič, J., Fonović, U. P., Nanut, M. P., Jakoš, T., Senjor, E., & Kos, J. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009013 · Cited by 133
“Additionally, SARS-CoV PL has been shown to inhibit interferon regulatory factor 3 phosphorylation early in the IFN-I signaling pathway [57, 58].”
BackgroundPathogenesis of Murine Coronavirus in the Central Nervous System
Bender, S. J., & Weiss, S. R. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9202-2 · Cited by 117
“Indeed, several studies have demonstrated that the PLP of SARS-CoV inhibits both the IRF3 and NF-κB pathways (Devaraj et al. 2007; Frieman et al. 2009).”
BackgroundRegulation of RIG-I-like receptor signaling by host and viral proteins
Chiang, J. J., Davis-Gardner, M. E., & Gack, M. U. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.06.005 · Cited by 134
“PLP’s DUB activity was shown to play a major role in IFN antagonism [117,118].”
Cascarina, S. M., & Ross, E. D. (2020) · The FASEB Journal · doi:10.1096/fj.202001351 · Cited by 127
van Kasteren, P. B., Bailey-Elkin, B. A., James, T. W., Ninaber, D. K., Beugeling, C., Khajehpour, M., Snijder, E. J., Mark, B. L., & Kikkert, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218464110 · Cited by 131
“The replicase polyproteins of coronaviruses harbor one or two papain-like proteases (PLpros) that participate in polyprotein maturation and presumably promote evasion of innate immunity by means of their DUB activity (32, 34, 37, 73).”
BackgroundTundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 125
Metadata
- Authors
- Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., & Li, K.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Loyola University Chicago (US)
- Lady Davis Institute for Medical Research (CA)
- Corresponding author
- Li, Kui
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 282
- Issue
- 44
- Pages
- 32208-32221
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2756044
- OpenAlex
- W190626844
- Cited by
- 411
- References
- 80
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 14 · 2023: 17 · 2022: 37 · 2021: 72 · 2020: 71 · 2019: 9 · 2018: 5 · 2017: 14 · 2016: 9 · 2015: 9 · 2014: 30 · 2013: 18 · 2012: 13
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4687 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai30039-19-0-2)
- National Institute on Drug Abuse (DA-018054, R21DA018054)
- National Institute of Allergy and Infectious Diseases (P01AI060915, AI060915, AI30039, AI-069285, AI 45798, AI057156, N01-AI-030039, U54AI057156, R01AI069285, R01AI045798)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- SARS-CoV, IRF3, papain-like protease, type I interferon, innate immune evasion, interferon antagonism, IRF3 phosphorylation, TLR3, IFN-stimulated genes, lung epithelial cells, viral pathogenesis
- MeSH terms
- Animals, Bronchi, Cell Line, Humans, Immunity, Innate, Interferon Type I, Peptide Hydrolases, Viral Proteins, Protein Structure, Tertiary, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Interferon Regulatory Factor-3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.